Gilead Sciences | GILD - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.52B 258M 2026-09
Agios Pharmaceuticals USD 155.3M 24.53M 2026-06
ALKERMES USD 1.86B 56.17M 2026-09
Alnylam Pharmaceuticals USD 1.11B 52.78M 2026-09
Amgen USD 5.69B 6B 2026-09
Biogen USD 2.32B 663.6M 2026-09
BioMarin Pharmaceutical USD 819.04M 5.5B 2026-09
Bristol-Myers Squibb USD 23.4B 1.08B 2026-09
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.52B 496M 2026-06
Gilead Sciences USD 13.04B 9.09B 2026-09
GlaxoSmithKline GBP 6.03B 227M 2026-09
Glaxosmithkline GBP 6.76B 1.42B 2026-09
Incyte USD 5.64B 4.67B 2026-09
J&J USD 18.93B 1.09B 2026-09
Merck USD 10.75B 5.02B 2026-09
Moderna USD 1.18B 223M 2026-09
Neurocrine Biosciences USD 779.7M 40.6M 2026-09
Novartis USD 9.88B 325M 2026-09
Pfizer USD 89B 3.81B 2026-09
PTC Therapeutics USD 211.54M 15.12M 2026-06
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 10.51B 598M 2026-09
Sarepta Therapeutics USD 390.39M 2.43M 2026-09
United Therapeutics USD 6.28B 124.3M 2026-09
Vertex Pharmaceuticals USD 2.18B 118.2M 2026-09